Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Jan:147:e156.
doi: 10.1017/S0950268818003679.

The effectiveness of vaccination to prevent the papillomavirus infection: a systematic review and meta-analysis

Herney Andrés García-Perdomo  1 , Julio Cesar Osorio  2 , Adrian Fernandez  3 , James Alejandro Zapata-Copete  4 , Andrés Castillo  5
Affiliations
Meta-Analysis

The effectiveness of vaccination to prevent the papillomavirus infection: a systematic review and meta-analysis

Herney Andrés García-Perdomo et al. Epidemiol Infect. 2019 Jan.

Abstract

Our purpose was to determine the effectiveness and harms of vaccination in patients with any sexual history to prevent the prevalence of papillomavirus infection. A search strategy was conducted in the MEDLINE, CENTRAL, EMBASE and LILACS databases. Searches were also conducted in other databases and unpublished literature. The risk of bias was evaluated with the Cochrane Collaboration's tool. Analysis of fixed effects was conducted. The primary outcome was the infection by any and each human papillomavirus (HPV) genotype, serious adverse effects and short-term adverse effects. The measure of the effect was the risk difference (RD) with a 95% confidence interval (CI). The planned interventions were bivalent vaccine/tetravalent/nonavalent vs. placebo/no intervention/other vaccines. We included 29 studies described in 35 publications. Bivalent HPV vaccine offers protection against HPV16 (RD -0.05, 95% CI -0.098 to -0.0032), HPV18 (RD -0.03, 95% CI -0.062 to -0.0004) and HPV16/18 genotypes (RD of -0.1, 95% CI -0.16 to -0.04). On the other side, tetravalent HPV vaccine offered protection against HPV6 (RD of -0.0500, 95% CI -0.0963 to -0.0230), HPV11 (RD -0.0198, 95% CI -0.0310 to -0.0085). Also, against HPV16 (RD of -0.0608, 95% CI -0.1126 to -0.0091) and HPV18 (RD of -0.0200, 95% CI -0.0408 to -0.0123). There was a reduction in the prevalence of HPV16, 18 and 16/18 genotypes when applying the bivalent vaccine, with no increase in adverse effects. Regarding the tetravalent vaccine, we found a reduction in the prevalence of HPV6, 11, 16 and 18 genotypes, with no increase in adverse effects.

Keywords: Human papillomavirus; meta-analysis; systematic review; vaccine.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Flowchart for selected studies.
Fig. 2.
Fig. 2.
Risk of bias assessment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lowy DRD (2016) HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. The Journal of Clinical Investigation 126, 5–11. - PMC - PubMed
    1. Joura EA et al. (2015) A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine 372, 711–723. - PubMed
    1. Wang CJ and Palefsky JM (2015) Human papillomavirus (HPV) infections and the importance of HPV vaccination. Current Epidemiology Reports 2, 101–109. - PMC - PubMed
    1. Kessels SJM et al. (2012) Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine 30, 3546–3556. - PubMed
    1. Lopalco P (2016) Spotlight on the 9-valent HPV vaccine. Drug Design, Development and Therapy 11, 35–44. - PMC - PubMed

MeSH terms

Substances